May 6 (Reuters) - Australian biotech firm CSL Ltd (CSL) said on Wednesday it will start local development of an immunoglobulin product to treat serious cases of COVID-19, the disease caused by the novel coronavirus.
The company's unit CSL Behring will develop the immunoglobulin product at its Melbourne-based Broadmeadows facility using antibodies from plasma collected from people who have recovered from COVID-19, CSL said in a statement on its website.
CSL expects around 800 plasma donations will be needed to produce enough immunoglobulin to treat around 50-100 seriously ill people under the clinical trial, it said.
News: CSL Australia's CSL to start work on immunoglobulin product to treat COVID-19
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$273.30 |
Change
-5.150(1.85%) |
Mkt cap ! $132.0B | |||
| Open | High | Low | Value | Volume |
| $275.10 | $275.24 | $272.37 | $199.1M | 726.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 200 | $273.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $273.34 | 12 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$273.21 |
Change
-5.150 ( 1.93 %) |
||||
| Open | High | Low | Volume | ||
| $275.24 | $275.24 | $272.38 | 30785 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| CSL (ASX) Chart |